|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
Cytotoxic T lymphocytes (CTLs) are an important defense against human immunodeficiency virus (HIV) type 1 but ultimately fail to control infection. To determine whether more efficient sustained immunity is induced by suppressing replication, the evolution of T cell phenotypes and HIV-specific CD8+ lymphocytes was prospectively investigated in 41 patients initiating combination therapy. Suppression of viremia to <200 copies/mL was associated with increases in naive cells (CD45RA+62L+) and declines in activated T cells (CD95+ cell counts and CD38+ HLA-DR+). HIV-specific tetramer-staining CD8+ T cells were detected in 6 of 10 HLA-A*0201-positive persons, which declined in 5 with treatment. CTL precursor frequencies were markedly consistent before and after treatment. Eight (72%) of 11 recognized > or =1 immunodominant epitope, representing either a new or an increased CTL response after treatment. Thus, activated CD8+ T cells, including those recognizing immunodominant epitopes, decline with combination therapy. However, the overall level of antigen-specific cells that are capable of differentiating into effectors remains stable, and the recognition of new epitopes may occur.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD45,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunodominant Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Indinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Tyrosine Phosphatase...,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:CollierA CAC,
pubmed-author:HirschM SMS,
pubmed-author:HoeringAA,
pubmed-author:KurodaM JMJ,
pubmed-author:LetvinN LNL,
pubmed-author:LiftonM AMA,
pubmed-author:MarkelSS,
pubmed-author:McElrathM JMJ,
pubmed-author:RHIMJ SJS,
pubmed-author:SabathD EDE,
pubmed-author:SchmitzJ EJE,
pubmed-author:SevinAA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
183
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
722-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11181148-Anti-HIV Agents,
pubmed-meshheading:11181148-Antigens, CD45,
pubmed-meshheading:11181148-CD4 Lymphocyte Count,
pubmed-meshheading:11181148-CD8-Positive T-Lymphocytes,
pubmed-meshheading:11181148-Dose-Response Relationship, Immunologic,
pubmed-meshheading:11181148-Drug Therapy, Combination,
pubmed-meshheading:11181148-Epitopes, T-Lymphocyte,
pubmed-meshheading:11181148-Flow Cytometry,
pubmed-meshheading:11181148-HIV Infections,
pubmed-meshheading:11181148-HIV-1,
pubmed-meshheading:11181148-HLA-DR Antigens,
pubmed-meshheading:11181148-Humans,
pubmed-meshheading:11181148-Immunodominant Epitopes,
pubmed-meshheading:11181148-Immunohistochemistry,
pubmed-meshheading:11181148-Immunophenotyping,
pubmed-meshheading:11181148-Indinavir,
pubmed-meshheading:11181148-Lamivudine,
pubmed-meshheading:11181148-Prospective Studies,
pubmed-meshheading:11181148-Protein Tyrosine Phosphatase, Non-Receptor Type 1,
pubmed-meshheading:11181148-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:11181148-Viral Load,
pubmed-meshheading:11181148-Zidovudine
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.
|
|
pubmed:affiliation |
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|
